The abstract is read at the publisher; the summary is JClub's.
Transient p38 MAPK inhibition during CRISPR-Cas9 editing of human HSPCs reduces micronuclei and lowers long-term mutational burden without increasing detectable structural genome alterations.
- Why it matters: Ex vivo editing of HSPCs can trigger nuclease- and culture-associated DNA damage, risking chromosomal instability, mis-integration, and impaired long-term stem cell function that limits clinical translation.
- What they did: The study tested transient p38 MAPK inhibition during clinically relevant CRISPR-Cas9 editing, using comprehensive genotoxicity assays (large on-target deletions, AAV mis-integration, and CAST-seq translocation mapping) plus long-term xenotransplantation with whole-exome sequencing.
- The result: p38i significantly reduced micronuclei and was linked to a reduced mutational burden after xenotransplantation, with no measurable differences in gene editing-associated structural alterations.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.